Natalizumab for Multiple Sclerosis in Clinical Practice in Germany - TYSTART

Trial Profile

Natalizumab for Multiple Sclerosis in Clinical Practice in Germany - TYSTART

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms TYSTART
  • Sponsors Biogen
  • Most Recent Events

    • 16 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top